On December 12, 2019, Avinger, Inc. appointed Tamara Elias, MD, as a Class III director, effective December 12, 2019, to serve for a term expiring at the Company's 2021 Annual Meeting of Stockholders, or until her earlier death, resignation or removal. Dr. Elias will serve on the Compensation Committee and Nominating and Corporate Governance Committee of the Company's Board of Directors. Dr. Elias was appointed to fill a vacancy created by the Board's adoption of a resolution to increase the number of directors of the Company from four to five directors. In connection with her appointment as a director, on December 12, 2019, the company entered into an Offer Letter with Dr. Elias, pursuant to which Dr. Elias agreed to serve as a director. Dr. Elias most recently served as Vice President of Clinical Product Development at Aetna.
Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. It has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).
AVINGER, INC. 
